Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 

 Table of Contents  
ORIGINAL ARTICLE
Year : 2009  |  Volume : 5  |  Issue : 4  |  Page : 267-271

Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors


1 Department of Surgical Oncology, Cancer Institute (WIA), Chennai, India
2 Department of Medical Oncology, Cancer Institute (WIA), Chennai, India

Date of Web Publication11-Feb-2010

Correspondence Address:
Ramakrishnan A Seshadri
Department of Surgical Oncology, Cancer Institute (WIA), Annexe Campus, No.18, Sardar Patel Road, Guindy, Chennai - 600 036
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0973-1482.59905

Rights and Permissions
 > Abstract 

Aim : To study the role of neoadjuvant imatinib mesylate in downsizing tumors in patients with locally advanced nonmetastatic gastrointestinal stromal tumors (GISTs), thus improving the possibility of complete resection.
Materials and Methods : We used neoadjuvant imatinib in six patients with locally advanced GISTs, at a dose of 400 mg daily, given orally in all patients for a median period of 3.5 months (range 1-20 months). All patients had a computerized tomography scan (CT scan) once before starting the treatment and a repeat CT scan 1 month after starting imatinib. Some patients had another CT scan done at 3 months. The tumor volume was calculated using the formula V=4/3 πr 3 .
Results : Following imatinib therapy, the median reduction in the tumor volume was 40% (range 20-50%). Four of the six patients underwent successful complete resection of the tumor following neoadjuvant imatinib for a median period of 2 months, and are disease free after a median follow-up of 10.5 months (range 3-20 months). Two patients in whom the tumors were deemed to be operable after downsizing refused surgery and are continuing imatinib. Imatinib did not produce serious toxicity in any patient.
Conclusion : Neoadjuvant imatinib can be used successfully in patients with locally advanced nonmetastatic GISTs to improve the rates of complete resection and reduce the chance of tumor spill. The optimal duration of neoadjuvant treatment needs to be tailored based on response assessment at frequent intervals to identify the ideal window period for surgery.

Keywords: Gastrointestinal stromal tumors, imatinib, neoadjuvant, surgery


How to cite this article:
Seshadri RA, Rajendranath R. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors. J Can Res Ther 2009;5:267-71

How to cite this URL:
Seshadri RA, Rajendranath R. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors. J Can Res Ther [serial online] 2009 [cited 2020 Jul 7];5:267-71. Available from: http://www.cancerjournal.net/text.asp?2009/5/4/267/59905


 > Introduction Top


Gastrointestinal stromal tumors (GISTs) are the commonest mesenchymal neoplasm of the gastrointestinal tract. [1] Surgery is the standard treatment in localized nonmetastatic GISTs. [2],[3] At presentation, only 70-85% of GISTs are resectable [1],[4],[5] and 10-40% of the tumors invade the surrounding organs. [2] A large tumor size increases the chance of tumor spill and reduces the chance of complete resection. Incomplete resection and tumor spill are known to have a negative impact on the survival of patients with GISTs. [1],[4] Hence, increasing the rate of complete resection without tumor spill, and achieving this by a less radical surgery may improve the chances of survival in locally advanced GISTs. Imatinib mesylate (Gleevec, formerly STI571; Novartis Pharma AG, Basel, Switzerland), a small molecule in the 2-phenylaminopyrimidine class, has been approved for use in the treatment of metastatic GISTs by the United States Food and Drug Administration in 2001. [6] Our aim was to study the role of neoadjuvant imatinib mesylate in downsizing tumors in patients with locally advanced nonmetastatic GISTs, thus improving the chance of complete resection.


 > Materials and Methods Top


This is a prospective analysis of patients who were diagnosed to have histologically proven locally advanced nonmetastatic GISTs in our institution between 2007 and 2008. All the tumors had positive immunohistochemical staining for c-kit (Dakopats, Denmark). The tumors were considered locally advanced due to their large size with a suspicious involvement of adjacent organs or major blood vessels which would have required a major multiorgan resection with a possibility of tumor spill and incomplete resection. The dose of imatinib used was 400 mg per day, given orally. All the patients had a baseline computerized tomography (CT) scan of the abdomen before starting imatinib therapy and subsequent CT scans were performed at the end of 1 month of treatment and again at 3 months in some patients. The volume of the tumor was calculated using the formula V = 4/3 πr3 , where "r" represents the maximum dimension of the tumor as measured on the CT scan. Surgery was performed when the imaging revealed adequate downsizing of the tumor to permit a less extensive, but complete surgical resection, as assessed by the surgeon, or when two serial CT scans did not show an appreciable decrease in the tumor volume. One patient underwent an emergency surgery due to bleeding from the tumor. Adjuvant imatinib was used in 75% of the patients who underwent a surgery. Survival was calculated from the day of the surgery till the date of the last follow-up.


 > Results Top


Six patients with locally advanced nonmetastatic GISTs received neoadjuvant imatinib in our institution between 2007 and 2008. The clinical and treatment characteristics of these patients are detailed in [Table 1]. None of the six patients had any serious adverse effects due to imatinib. All the six patients had a partial radiological response [Figure 1], whereas a complete radiological response was not observed in any patient. The median reduction in the tumor volume following imatinib therapy was 40% (range 20-50%). Four of the six patients underwent surgical resection of the residual tumor. Two patients declined surgery even though their tumors had considerably reduced in size to permit a complete resection, and are continuing imatinib. All the four patients who underwent a surgery had a complete resection without tumor spill and with negative margins of resection. Multiorgan resection was needed in two patients. In the remaining two patients, even though the pre-imatinib treatment CT showed a suspicious infiltration of adjacent organs, multiorgan resection was not needed. One patient with a proximal gastric tumor had an attempt at a conservative procedure to spare the gastroesophageal junction, but this was not successful and he finally underwent a total gastrectomy. There was no postoperative morbidity or mortality. A partial pathological response was observed in all four patients, with residual viable tumor cells mixed with varying degrees of myxoid changes, necrosis and hemorrhage in the residual tumor. None of the patients had a complete pathological response. All the operated patients are disease free after a median follow-up of 10.5 months (range 3-20).


 > Discussion Top


GISTs account for 6% of all sarcomas. [1] They arise from the precursor mesenchymal stem cells residing in the wall of the gut, which also differentiate into the interstitial cells of Cajal. [7] At the molecular level, GISTs have a gain of function mutation in the KIT protooncogene [8] which results in a ligand-independent activation of the abnormal KIT protein, causing uninterrupted tyrosine kinase-mediated intracellular signaling. Surgery is the standard initial treatment for nonmetastatic GISTs and entails a complete resection of the tumor without tumor spill. [2],[3],[5],[9] A complete resection improves the survival in patients with GISTs. [1],[4],[10],[11] Pierie et al. reported 5-year survival rates of 42% and 9% after a complete and an incomplete resection of GIST, respectively. [11] In their series of 200 patients with GISTs, Dematteo et al.[1] reported a median survival of 66 months after a complete resection and 22 months after an incomplete resection. Tumor spill during the surgery also increases the chance of peritoneal recurrence and reduces the survival. Ng et al. reported that tumor rupture reduced the median survival from 46 to 17 months, which was comparable to the median survival after an incomplete resection (21 months). [4]

However, only 70-85% of patients with localized GISTs can undergo a complete resection. [1],[10],[11],[12] Crosby et al.[10] reported that 48% of patients in their series had locally advanced nonmetastatic disease and of these, only 79% could undergo a complete resection. They also reported that the survival of patients with locally advanced disease was not significantly different from that of patients with localized disease. Therefore, methods to downsize locally advanced tumors in order to bring them into the purview of surgery may improve the rates of a complete resection and hence the survival in patients with locally advanced GISTs. Imatinib mesylate, a small multiringed molecule, is a KIT-receptor tyrosine kinase inhibitor which competes with ATP for its kinase-binding site, and prevents the kinase from transferring phosphate from ATP to tyrosine residues of substrates, thus inhibiting downstream signaling. [2] It has been approved for use in metastatic GISTs, [6] where it has been shown to decrease the size of the tumors by at least 50%. [13],[14] The first report of neoadjuvant imatinib in locally advanced GISTs was by Bumming et al. [15] He reported a patient with an unresectable ileal GIST with liver metastasis. After the use of neoadjuvant imatinib for 12 weeks, the primary tumor had reduced in size from 35 to 18 cm, and was resected completely. However, there are very few reports of the use of neoadjuvant imatinib exclusively in locally advanced nonmetastatic GISTs [Table 2]. Katz et al.[16] described the successful complete resection of two locally advanced unresectable nonmetastatic gastric GISTs after the use of neoadjuvant imatinib for 7 months, which led to an almost 50% reduction in the tumor size. The largest series so far comprises only 14 patients. [19] In our series, all the patients who underwent a surgery had a complete resection. The median reduction in the tumor volume in our series was probably less due to the shorter duration of treatment with imatinib.

The definition of unresectable GISTs varies in different reports. Andtbacka et al.[20] defined unresectability as the presence of radiological evidence of a significant involvement of a single organ with size ≥5 cm or extension to adjacent organs. Another report defines unresectability on the basis of size, need for adjacent organ resection, or major vessel involvement. [17] In the present series, the tumors were considered unresectable due to the large size and the involvement of adjacent organs and/or major blood vessels. The European Society of Medical Oncology (ESMO) consensus conference on GISTs stated that there is no reliable definition for locally advanced nonmetastatic versus localized, resectable disease due to diversity in the size, site, and extension of these lesions. [3] The dose of imatinib that we used (400 mg) is similar to that used in other series. It has, however, been shown that GISTs harboring exon 11 KIT mutations respond better to imatinib and also have a better survival compared to those with exon 9 KIT mutation or no detectable mutation in KIT or platelet-derived growth factor receptor alpha (PDGFRA). [24] We did not include mutation analysis as a part of our study since it is not mandatory for diagnosing GISTs, especially since all our patients had positive immunostaining for c-kit. Also, we started with the standard dose of imatinib (400 mg) and in case there was no clinical or radiological response to this dose, we had the option of increasing the dose. However, recent evidence has shown that patients with exon 9 mutation may benefit from a dose of 800 mg imatinib daily. [25] Hence, analysis of KIT and PDGFRA mutations can be useful in determining the dose and possible resistance to imatinib in the neoadjuvant sitting as well and should be incorporated in future studies of neoadjuvant imatinib. The response to imatinib is predicted by a combination of symptomatic improvement (clinical response), decrease in the tumor Houndsfield units on the CT scan (radiological response), and reduced FDG uptake in a positron emission tomography (PET) scan (metabolic response). [3] A CT scan is the imaging modality of choice in determining response, although for a short-term follow-up, a PET scan may predict the response better. It has been reported that the RECIST criteria for the assessment of response to treatment in solid tumors is unreliable for monitoring GISTs during imatinib treatment as it underestimates the tumor response. [26] The Choi criteria, which is a 10% decrease in the unidimensional tumor size or a 15% decrease in the tumor density on contrast-enhanced CT, have been reported to be more accurate and sensitive than RECIST criteria for assessing response to imatinib. [27] A FDG-PET scan is sensitive and specific for early tumor response, but it may be inaccurate in predicting residual disease. [20],[26] CT findings in responding tumors include a reduction in the tumor density, in the solid enhancing nodules, and in the tumor vessels. [3],[20],[26]

The optimal timing of the surgery following neoadjuvant imatinib is debatable. Theoretically, the surgery should be performed in the window period, i.e. after maximum response, but before the development of secondary resistance. This is usually around 6-12 months. [21,28] However, secondary KIT mutations have been identified even after 10 months of neoadjuvant imatinib therapy. [29] Hence, surgery should be performed as soon as there is sufficient shrinkage to perform complete resection. [3] The cessation of tumor shrinkage on successive imaging or CT findings like the formation of new nodules or tumor growth after a period of shrinkage may represent the beginning of secondary resistance and should prompt evaluation for surgery. [29]

Practically, therefore, surgical resection is best performed when two successive radiological imaging studies done at 2 to 3 monthly intervals do not show further regression in the tumor. [17],[20] The main advantage of neoadjuvant imatinib in locally advanced GISTs is the reduction in the tumor volume, which allows a more complete and less extensive resection. [9],[20] It can also allow organ conservation, especially in GISTs of the rectum or gastroesophageal junction. [23],[30] It has also been suggested that due to the bystander effect of imatinib on vascular endothelial growth factor, there may be an antiangiogenic effect which may reduce the possibility of bleeding during surgery. [31] Neoadjuvant imatinib has the possibility of eradicating micrometastatic disease. [9] Debulking with imatinib may help optimize the timing of surgery and avoid emergency surgery in patients with large GISTs which predisposes them to hemorrhage or rupture. [5] However, the disadvantages could include a sudden increase in the size or increased chance of rupture due to treatment-induced myxoid changes, and chance of secondary mutation. [3],[28],[29]

The preliminary results of the RTOG 0132/ACRIN 6665 nonrandomized prospective study of neoadjuvant imatinib have been recently published. [32] This trial used 600 mg imatinib as neoadjuvant therapy in patients with potentially resectable intermediate- to high-risk primary GISTs and potentially resectable recurrent/metastatic GISTs. In the 30 patients with primary GISTs, neoadjuvant imatinib induced a 7% partial response rate. The 3-year progression-free survival was 68% and estimated overall survival at 3 years was 84% in this subgroup. A complete resection was possible in 77% of these patients and partial organ preservation and function sparing was reported in many patients. Our study is different from this trial as we have only included patients with unresectable nonmetastatic primary GISTs. Although our series is small, we have been able to demonstrate the successful use of neoadjuvant imatinib in unresectable nonmetastatic GISTs. However, a longer follow-up is needed to determine the effect of neoadjuvant imatinib on long-term survival in these patients.


 > Conclusion Top


In summary, neoadjuvant imatinib in locally advanced nonmetastatic unresectable GISTs can help to downsize the tumor, thereby increasing the rates of complete resection without spill and reducing the extent of surgery. A close interaction between the surgeon and the medical oncologist is needed to ensure that surgery is performed at the appropriate time, following a major response but before the development of resistance. The use of KIT mutation analysis may help in determining the sensitivity to imatinib and in choosing the appropriate dose.



 
 > References Top

1.DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-8.  Back to cited text no. 1
[PUBMED]  [FULLTEXT]  
2.Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G. Management of malignant gastrointestinal stromal tumors. Lancet Oncol 2002;3:655-64.  Back to cited text no. 2
[PUBMED]  [FULLTEXT]  
3.Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos AP, et al. Consensus meeting for the management of gastrointestinal stromal tumors: Report of the GIST consensus conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005;16:566-78.  Back to cited text no. 3
[PUBMED]  [FULLTEXT]  
4.Ng EH, Pollock RE, Munsell MF, Atkinson EN, Romsdahl MM. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Ann Surg 1992;215:68-77.   Back to cited text no. 4
[PUBMED]  [FULLTEXT]  
5.Eisenberg BL, Judson I. Surgery and imatinib in the management of GIST: Emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol 2004;11:465-75.   Back to cited text no. 5
[PUBMED]  [FULLTEXT]  
6.Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G, et al. Approval summary: Imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 2002;8:3034-8.   Back to cited text no. 6
[PUBMED]  [FULLTEXT]  
7.Kindblom LG, Remotti HE, Aldenborg F, Meis Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): Gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998;152:1259-69.  Back to cited text no. 7
    
8.Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-KIT in human gastrointestinal stromal tumors. Science 1998;279:577-80.  Back to cited text no. 8
[PUBMED]  [FULLTEXT]  
9.Heinrich MC, Corless CL. Gastric GI stromal tumors (GISTs): The role of surgery in the era of targeted therapy. J Surg Oncol 2005;90:195-207.  Back to cited text no. 9
[PUBMED]  [FULLTEXT]  
10.Crosby JA, Catton CN, Davis A, Couture J, O'Sullivan B, Kandel R, et al. Malignant gastrointestinal stromal tumors of the small intestine: A review of 50 cases from a prospective database. Ann Surg Oncol 2001;8:50-9.  Back to cited text no. 10
[PUBMED]  [FULLTEXT]  
11.Pierie JP, Choudry U, Muzikansky A, Yeap BY, Souba WW, Ott MJ. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 2001;136:383-9.  Back to cited text no. 11
[PUBMED]  [FULLTEXT]  
12.Roberts PJ, Eisenberg B. Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer 2002;38:S37-8.  Back to cited text no. 12
[PUBMED]  [FULLTEXT]  
13.Van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Padiola E, Dimitrijevic S et al. Safety and efficacy of imatinib mesylate (STI571) in metastatic gastrointestinal stromal tumors: A phase I study. Lancet 2001;358:1421-3.  Back to cited text no. 13
    
14.Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts JP, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.  Back to cited text no. 14
    
15.Bumming P, Andersson J, Meis-Kindblom JM, Klingenstierna H, Engström K, Stierner U, et al. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumors (GIST) with imatinib: A centre-based study of 17 patients. Br J Cancer 2003;89:460-4.  Back to cited text no. 15
    
16.Katz D, Segal A, Alberton Y, Jurim O, Reissman P, Catane R, et al. Neoadjuvant imatinib for unresectable gastrointestinal stromal tumor. Anticancer Drugs 2004;15:599-602.  Back to cited text no. 16
[PUBMED]  [FULLTEXT]  
17.Bonvalot S, Eldweny H, Le Péchoux C, Vanel D, Terrier P, Cavalcanti A, et al. Impact of surgery on advanced Gastrointestinal Stromal Tumors (GIST) in the Imatinib era. Ann Surg Oncol 2006;13:1596-603.   Back to cited text no. 17
    
18.Rutkowski P, Nowecki Z, Nyckowski P, Dziewirski W, Grzesiakowska U, Nasierowska-Guttmejer A, et al. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg On col 2006;93:304-11.  Back to cited text no. 18
    
19.Hohenberger P, Langer C, Pistorius S, Iesalnieks I, Wardelmann E, Reichardt P, et al. Indication and results of surgery following imatinib treatment of locally advanced or metastatic GI stromal tumors (GIST). J Clin Oncol 2006 ASCO Annual Meeting Proceedings Part-I. Vol 24, No 18S (June 20 Supplement), 2006: 9500.  Back to cited text no. 19
    
20.Andtbacka RH, Ng CS, Scaife CL, Cormier JN, Hunt KK, Pisters PW, et al. Surgical treatment of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 2007;14:14-24.  Back to cited text no. 20
[PUBMED]  [FULLTEXT]  
21.Gronchi A, Fiore M, Miselli F, Lagonigro MS, Coco P, Messina A, et al. Surgery of residual disease following molecular targeted therapy with imatinib mesylate in advanced/ metastatic GIST. Ann Surg 2007;245:341-6.   Back to cited text no. 21
[PUBMED]  [FULLTEXT]  
22.Cavaliere D, Vagliasindi A, Mura G, Framarini M, Giorgetti G, Solfrini G, et al. Down staging of a gastric GIST by neoadjuvant imatinib and endoscopic assisted laparoscopic resection. Eur J Surg Oncol 2007;33:1044-6.  Back to cited text no. 22
[PUBMED]  [FULLTEXT]  
23.Staiger WI, Ronellenfitsch U, Kaehler G, Schildhaus HU, Dimitrakopoulou-Strauss A, Schwarzbach MH, et al. The Merendino procedure following preoperative imatinib mesylate for locally advanced gastrointestinal stromal tumor of the esophagogastric junction. World J Surg Oncol 2008;6:37.   Back to cited text no. 23
[PUBMED]  [FULLTEXT]  
24.Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-9.  Back to cited text no. 24
[PUBMED]  [FULLTEXT]  
25.Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008;26:5360-7.  Back to cited text no. 25
[PUBMED]  [FULLTEXT]  
26.Choi H, Charnsangavej C, Faria SC, Tamm EP, Benjamin RS, Johnson MM, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: A quantitative analysis correlated with FDG-PET findings. AJR Am J Roentgenol 2004;183:1619-28.  Back to cited text no. 26
    
27.Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, et al. Response of gastrointestinal stromal tumors (GISTs) to imatinib by Choi criteria and response evaluation criteria in solid tumors (RECIST) as surrogates for survival and time to progression. J Clin Oncol 2006 ASCO Annual Meeting Proceedings Part-I. Vol 24, No 18S (June 20 Supplement), 2006: 9508.  Back to cited text no. 27
    
28.Loughrey MB, Mitchell C, Mann GB, Michael M, Waring PM. Gastrointestinal stromal tumor treated with neoadjuvant imatinib. J Clin Path 2005;58:779-81  Back to cited text no. 28
[PUBMED]  [FULLTEXT]  
29.Haller F, Detken S, Schulten HJ, Happel N, Gunawan B, Kuhlgatz J, et al. Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumors (GISTs) with respect to imatinib resistance caused by secondary KIT mutations. Ann Surg Oncol 2007;14:526-32.   Back to cited text no. 29
[PUBMED]  [FULLTEXT]  
30.Lo SS, Papachristou GI, Finkelstein SD, Conroy WP, Schraut WH, Ramanathan RK. Neoadjuvant imatinib in gastrointestinal stromal tumor of the rectum: Report of a case. Dis Colon Rectum 2005;48:1316-9.  Back to cited text no. 30
    
31.Eisenberg BL. Combining imatinib with surgery in gastrointestinal stromal tumors: Rationale and ongoing trials. Clin Colorectal Cancer 2006;6:S24-9.  Back to cited text no. 31
[PUBMED]  [FULLTEXT]  
32.Eisenberg BL, Harris J, Blanke CD, Demetri GD, Heinrich MC, Watson JC, et al. Phase II trial of neoadjuvant/ adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665. J Surg Oncol 2009;99:42-7.  Back to cited text no. 32
[PUBMED]  [FULLTEXT]  


    Figures

  [Figure 1]
 
 
    Tables

  [Table 1], [Table 2]


This article has been cited by
1 Radiologic assessment of earliest, best, and plateau response of gastrointestinal stromal tumors to neoadjuvant imatinib prior to successful surgical resection
S.H. Tirumani,A.B. Shinagare,J.P. Jagannathan,K.M. Krajewski,N.H. Ramaiya,C.P. Raut
European Journal of Surgical Oncology (EJSO). 2013;
[Pubmed] | [DOI]
2 Esophageal gastrointestinal stromal tumor: Report of 7 patients
Shinagare, A.B., Zukotynski, K.A., Krajewski, K.M., Jagannathan, J.P., Butrynski, J., Hornick, J.L., Ramaiya, N.H.
Cancer Imaging. 2012; 12(1): 100-108
[Pubmed]
3 Prolonged Therapy with Imatinib Mesylate before Surgery for Advanced Gastrointestinal Stromal Tumor Results of a Phase II Trial
C. Doyon,L. Sidéris,G. Leblanc,Y. E. Leclerc,D. Boudreau,P. Dubé
International Journal of Surgical Oncology. 2012; 2012: 1
[Pubmed] | [DOI]
4 Prolonged therapy with imatinib mesylate before surgery for advanced gastrointestinal stromal tumor results of a phase II trial
Doyon, C. and Sidéris, L. and Leblanc, G. and Leclerc, Y.E. and Boudreau, D. and Dubé, P.
International Journal of Surgical Oncology. 2012; 2012(761576)
[Pubmed]
5 Diagnosis, treatment and prognosis of gastrointestinal stromal tumors: An analysis of 67 cases
Xia, Z.-F., Chen, S.-F., Tao, K.-X., Cai, K.-L., Shuai, X.-M., Han, G.-X., Wang, J.-L., (...), Wang, G.-B.
World Chinese Journal of Digestology. 2010; 18(21): 2266-2270
[Pubmed]



 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

  >Abstract>Introduction>Materials and Me...>Results>Discussion>Conclusion>Article Figures>Article Tables
  In this article
>References

 Article Access Statistics
    Viewed3251    
    Printed171    
    Emailed0    
    PDF Downloaded424    
    Comments [Add]    
    Cited by others 5    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]